Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
about
Bcl-2 antagonists: a proof of concept for CLL therapyDynamics of Bcl-xL in water and membrane: molecular simulationsMito-priming as a method to engineer Bcl-2 addiction.Mitochondrial apoptosis and BH3 mimeticsMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsThe copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphomaBM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivoMcl-1 is essential for the survival of plasma cells.A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survivalBoth leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice.Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan.Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesVenetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsDirected elimination of senescent cells by inhibition of BCL-W and BCL-XLCell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsRapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.A time to kill: targeting apoptosis in cancer.BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.TIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2.Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic miceThe ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skinThe BCL-2 protein family, BH3-mimetics and cancer therapy.A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemiaLoss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer.Elevated Mcl-1 inhibits thymocyte apoptosis and alters thymic selection.Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1.Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological ToleranceNanotechnology inspired tools for mitochondrial dysfunction related diseases.BAK activation is necessary and sufficient to drive ceramide synthase-dependent ceramide accumulation following inhibition of BCL2-like proteins.BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitorsYeast techniques for modeling drugs targeting Bcl-2 and caspase family members.Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A.Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo.
P2860
Q26823996-6C0ACF5D-4799-4CDA-9BE9-BF6B38040DC6Q27304496-98D4BA23-07BA-4D4D-9FB7-0DAD3BAD37C5Q27334195-216DDD3F-A1A8-41BD-B055-88B8DDEF18F0Q28069552-0011985B-E5B8-495E-B1BA-9E1CC769AD94Q28075606-FFF8BC71-FD80-4CA0-BBC3-AA46D386FE17Q28389285-76D869B4-20ED-4375-A928-EDE76384B164Q28539452-4F212012-4E60-423D-80B7-76DDEE02D401Q30412677-5806036C-5711-4AA6-984B-0B865A0D467CQ31100573-E2EB25EE-8003-4476-8C92-6F09D0110CF4Q33412553-CA0286EB-E12D-4FE1-AC32-1A9A4C304AF5Q33412907-D1229595-6181-4B7F-936A-E1EE2A264C7AQ33413694-A289D518-2AFF-4127-B654-84F5FED03611Q33422543-E530FE3C-1618-444F-85F0-EEB425FF62E4Q33433407-0B9E1183-886D-43E0-BFBC-48C24DD12283Q33702409-F7BA6582-AB3F-418A-BA47-C54BAA182C1DQ33808800-364D5769-1E1E-49E8-BB29-CA8E1EF1D602Q34046604-4E7CCF40-C4C0-4F56-BE4B-64722BA053BDQ34135333-17202A5F-8005-456B-859F-1D667CDC8B78Q34374169-B04A50BE-C49B-4111-B399-C375869127EBQ35138968-DCBA1DF8-FD5B-40D3-A709-CE6A2DDDEB0BQ35251905-B780B2E1-8975-4EBA-A679-A19FF4932A3BQ35772248-D1256C2F-216D-47F4-B3D4-7C47279D89B5Q35941499-E8152603-49BE-4192-B1F4-2D09C2ACF5C8Q35966223-ADB0967F-919E-4F94-9C72-2DB71A39D232Q36067778-84FD0863-A08A-42E7-A1F3-FB0B15393CFFQ36276017-66ED2E32-1E6C-4685-B678-91D7553C5572Q36349985-4E829A61-4854-4C3A-8FC8-7AADBF52F96AQ36413318-9B6FBDD8-1EC8-41F0-A8D0-8E42770DE621Q36418705-37521A0D-787F-407F-BEB9-147855369EAFQ36544778-B4C69779-0FD0-4F85-BDB6-38B2C29B7081Q36546429-C0FACED1-9F14-48C1-94AA-60508356E6F3Q36546659-6221D710-602D-4313-AB8E-64102965ACD5Q36632500-3E69ED62-3902-4E42-BC34-C199F02F9BAEQ36703351-49B62AF1-074A-4C35-B46A-2703FDC0894AQ36813008-0E8A68FD-9D38-42D0-92CA-F7469F8BB1E2Q36866417-59CCA67A-E96B-4E05-BC7D-3706D20C795AQ36907080-3C42CEA0-B189-4C71-BD68-5DD4A8F570ADQ37061433-7E5D3EAB-4AEA-4756-8B35-E390EC2D5385Q37092954-78D820DC-B581-4AFB-90F5-17EACE95B8F2Q37118668-850BBF5A-57D9-427E-856B-3E8EA27C1326
P2860
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Bcl-2, Bcl-x(L), and Bcl-w are ...... in lymphoid and leukemic cells
@ast
Bcl-2, Bcl-x(L), and Bcl-w are ...... in lymphoid and leukemic cells
@en
type
label
Bcl-2, Bcl-x(L), and Bcl-w are ...... in lymphoid and leukemic cells
@ast
Bcl-2, Bcl-x(L), and Bcl-w are ...... in lymphoid and leukemic cells
@en
prefLabel
Bcl-2, Bcl-x(L), and Bcl-w are ...... in lymphoid and leukemic cells
@ast
Bcl-2, Bcl-x(L), and Bcl-w are ...... in lymphoid and leukemic cells
@en
P2093
P2860
P50
P1433
P1476
Bcl-2, Bcl-x(L), and Bcl-w are ...... in lymphoid and leukemic cells
@en
P2093
Cassandra J Vandenberg
Chihunt Wong
David C S Huang
Lisa D Belmont
Mary J C Ludlam
Mikara Robati
Seong L Khaw
Stefan P Glaser
P2860
P304
P356
10.1182/BLOOD-2011-12-400929
P407
P50
P577
2012-04-26T00:00:00Z